The potential for crizotinib in non-small cell lung cancer: a perspective review
about
New modalities of cancer treatment for NSCLC: focus on immunotherapyCrizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.Genome Fusion Detection: a novel method to detect fusion genes from SNP-array data.Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung.Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic ModelMembrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.ALK gene copy number gain and its clinical significance in hepatocellular carcinoma.c-Met expression and activity in urogenital cancers - novel aspects of signal transduction and medical implications.Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.Kinase dysfunction and kinase inhibitors.Immunologic and clinical effects of targeting PD-1 in lung cancer.Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.Crizotinib in the management of advanced-stage non-small-cell lung cancer.Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer.Diagnosis and Molecular Classification of Lung Cancer.Computational Investigation and Experimental Validation of Crizotinib Resistance Conferred by C1156Y Mutant Anaplastic Lymphoma Kinase.TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787.Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics.ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients.[Advances of driver gene and targeted therapy of non-small cell lung cancer].
P2860
Q26829161-90924033-DB34-408D-A0C3-FEF3DA17DC35Q30400310-CA3F31EB-E52D-4FD7-9A67-2A739F30A54FQ33699594-794F8D62-9E3F-44DF-BA9A-33AB2BA88063Q34388696-ABB90BAB-452D-494F-9349-66F6BA2BE507Q34557870-70E19366-43B8-404B-87D5-75AA35A9E3ECQ34952066-4A9501A3-8F36-43EF-A6D4-BA8691B4CF00Q35151114-06A06496-95B0-4A54-A8D8-0F4D56945B6BQ36140933-BF9B9A63-9D36-4557-AE1A-A23BB00604D1Q37031569-17C70CA1-0B9E-44ED-B07B-CADBAC503A9EQ37454444-5CA56F7D-90F5-4244-BD2E-843FAC4F1F73Q37651008-C192021F-D1AC-4C9F-AA68-2F991E195FFEQ38002887-07BFB7C7-EEC8-4DE5-B605-16D51D94494EQ38008456-FE8A0632-83BA-48BF-AF4E-CFAC142E2458Q38033672-4619B97D-0C72-457C-B3D4-E5ED7CF485D9Q38074590-88292932-309F-4325-A257-D3431ABA9FADQ38075152-9215FD7A-18EC-47C7-8005-4510B38ADC78Q38201196-F958A290-69DA-44E0-B7E8-854916046FD8Q38214154-C62210D6-21E3-4B66-AEF7-99B042155183Q38372437-9272D6E4-8836-40E0-BF75-C4F32E548392Q38792120-F8755A27-86C2-4C1A-A062-5E0F401EA818Q38930336-AA8AB0A7-BB7E-4B2F-B01C-C81DE7E207F2Q39045137-A487910D-5B8F-40B3-8A67-16F4C4821D8EQ41133791-C2214744-C295-4EC2-83A6-E163EA65D401Q41153904-2AAD8709-FC61-42DE-A5DC-2F85705DFEB1Q43142869-76A49BEF-E544-46F6-B8E1-C4A551C6A0F9Q53583293-30E98048-58D4-4E88-B67C-7FDCAD333287Q55073653-A774B272-BFA4-4080-8DD5-8FC9975BD080Q55465064-C72A74EE-B25F-4D4E-9A8E-5C974C38EC1C
P2860
The potential for crizotinib in non-small cell lung cancer: a perspective review
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The potential for crizotinib in non-small cell lung cancer: a perspective review
@ast
The potential for crizotinib in non-small cell lung cancer: a perspective review
@en
type
label
The potential for crizotinib in non-small cell lung cancer: a perspective review
@ast
The potential for crizotinib in non-small cell lung cancer: a perspective review
@en
prefLabel
The potential for crizotinib in non-small cell lung cancer: a perspective review
@ast
The potential for crizotinib in non-small cell lung cancer: a perspective review
@en
P2860
P356
P1476
The potential for crizotinib in non-small cell lung cancer: a perspective review
@en
P2093
Yung-Jue Bang
P2860
P304
P356
10.1177/1758834011419002
P577
2011-11-01T00:00:00Z